- Set up treatment reminders for your medication or activity to focus on adherence with CF treatment regimens
- Allow for full customization based on dosing frequency so that the app can deliver accurate reminders throughout the user’s day, week, month
- View and edit your treatment tracking as required
Adherence Tracking and Analytics
- Treatment tracking function allows the user to record each time they have taken a dose, completed a treatment, or finished an activity
- Adherence data compiled and displayed in graphs, calendar, and reports allows users to see proficiency with their overall CF treatment regimen
- Export data for PDF use or share your progress via social media
Real-time air quality alerts deliver a convenient update about the current outside environment based on the user’s location. Air Quality Index (AQI) measurements are based on hourly readings for your location.
- 0-50 implies that air quality is considered as good and pollution poses little or no risk
- 51-100 implies that air quality is acceptable but poses a moderate health concern for people with respiratory disease
- 101-150 members of sensitive groups may experience health effects. The general public is less likely to be affected
- 151-200 indicates that air quality is unhealthy and members of sensitive groups may experience more serious health effects
- 201-300 and above indicates that it is very unhealthy and hazardous for everyone
TOBI PODHALER Resources
Access TOBI PODHALER Resources in the App
- Educational content focused on proper use of TOBI PODHALER
- View step-by-step video instructions on administration
- Information for TOBI PODHALER patient support programs such as PODCARE+ and Savings Card signup
TOBI® PODHALER® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.
Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV1) <25% or >80% predicted, or patients colonized with Burkholderia cepacia.
IMPORTANT SAFETY INFORMATION
TOBI PODHALER is contraindicated in patients with known hypersensitivity to any aminoglycoside.
Bronchospasm can occur with inhalation of TOBI PODHALER. Bronchospasm should be treated as medically appropriate.
Caution should be exercised when prescribing TOBI PODHALER to patients with known or suspected auditory, vestibular, renal, or neuromuscular dysfunction.
Ototoxicity, as measured by complaints of hearing loss or tinnitus, was reported by patients in the TOBI PODHALER clinical studies. Tinnitus may be a sentinel symptom of ototoxicity, and therefore the onset of this symptom warrants caution. Ototoxicity, manifested as both auditory and vestibular toxicity, has been reported with parenteral aminoglycosides. Vestibular toxicity may be manifested by vertigo, ataxia, or dizziness.
Caution should be exercised when prescribing TOBI PODHALER to patients with known or suspected renal dysfunction. Nephrotoxicity was not observed during TOBI PODHALER clinical studies but has been associated with aminoglycosides as a class.
TOBI PODHALER should be used cautiously in patients with neuromuscular disorders, such as myasthenia gravis or Parkinson’s disease, since aminoglycosides may aggravate muscle weakness because of a potential curare-like effect on neuromuscular function.
Aminoglycosides can cause fetal harm when administered to a pregnant woman. Patients who use TOBI PODHALER during pregnancy, or who become pregnant while taking TOBI PODHALER, should be apprised of the potential hazard to the fetus. The amount of tobramycin excreted in human breast milk is unknown. However, systemic absorption of tobramycin following inhaled administration is expected to be minimal. A decision should be made whether to discontinue nursing or TOBI PODHALER. TOBI may cause intestinal flora alteration. Advise a woman to monitor the breastfed infant for loose or bloody stools and candidiasis.
Patients receiving concomitant TOBI and parenteral aminoglycoside therapy should be monitored as clinically appropriate for toxicities associated with aminoglycosides as a class. Serum tobramycin levels should be monitored.
Concurrent and/or sequential use of TOBI PODHALER with other drugs with neurotoxic, nephrotoxic, or ototoxic potential should be avoided. Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. TOBI PODHALER should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.
In a clinical trial, the most commonly observed adverse events with TOBI PODHALER occurring at a frequency of at least 10%, were cough, lung disorder, productive cough, dyspnea, pyrexia, oropharyngeal pain, dysphonia, hemoptysis, and headache.
Please see full Prescribing Information